Kenvue (KVUE) Q4 Earnings Meet Estimates
Kenvue (KVUE) came out with quarterly earnings of $0.26 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.31 per share a year ago.
Kenvue sees 2025 profit below estimates as strong dollar, weak cough product sales hit
Consumer health company Kenvue forecast 2025 adjusted profit below Wall Street estimates on Thursday, hit by a stronger dollar and weak demand for its cough and cold products that include Tylenol and Benadryl.
Gear Up for Kenvue (KVUE) Q4 Earnings: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Kenvue (KVUE) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Kenvue (KVUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Kenvue (KVUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 High-Yield Dividend Kings Baby Boomers Count on for Safe Passive Income
With the youngest baby boomers (Americans born between 1946 and 1964) approaching retirement age, it's becoming increasingly important to focus on magnificent dividend stocks that will supply significant passive income either in or out of designated retirement accounts like IRAs.
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Being a long-term investor brings a unique peace of mind. It requires thinking in decades, not months or years, which allows an investor to focus on owning exceptional businesses.
Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?
Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A Bull Market Is Here: 2 Super Stocks Down 21% and 30% to Buy Right Now
Even with the recent bout of market volatility, 2024 has been a fantastic year for stocks. The S&P 500 index has delivered a dividend-adjusted total return of roughly 25% across this year's trading.
Kenvue: Lots Of Potential, But Short-Term Upside May Be Tapped Out (Rating Downgrade)
Kenvue's recent earnings showed improvements, but persistent headwinds, especially in the Skin, Health, & Beauty segment, suggest limited upside potential in the near term. Despite solid dividend growth and cost-cutting initiatives, higher interest rates and economic challenges in China continue to weigh on Kenvue's performance. Management's strategic moves, including increased online presence and partnerships with influencers, aim to combat headwinds and drive future growth.
Tylenol maker Kenvue hails efficiency gains as activist Starboard watches on
Kenvue Inc (NYSE:KVUE), the maker of Listerine, Tylenol, Aveeno and Band-Aid, reported slightly lower sales than expected but earnings were just above Wall Street estimates. The company has been in a more intense spotlight coming into these results after reports emerged that activist investor Starboard Value has taken a stake and is eyeing changes.
Kenvue, Inc. (KVUE) Q3 2024 Earnings Call Transcript
Kenvue, Inc. (NYSE:KVUE ) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ET Company Participants Sofya Tsinis - Head, IR Thibaut Mongon - CEO Paul Ruh - CFO Conference Call Participants Bonnie Herzog - Goldman Sachs Anna Lizzul - Bank of America Andrea Teixeira - J.P. Morgan Peter Grom - UBS Filippo Falorni - Citi Steve Powers - Deutsche Bank Keith Devas - Jefferies Nik Modi - RBC Capital Markets Korinne Wolfmeyer - Piper Sandler Jeremy Fialko - HSBC Operator Hello, and welcome to the Kenvue Third Quarter 2024 Earnings Conference Call.
Here's What Key Metrics Tell Us About Kenvue (KVUE) Q3 Earnings
Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
